{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Carcinoma+of+Stomach&page=14", "query": { "condition": "Solid Carcinoma of Stomach", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 340, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Carcinoma+of+Stomach&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Carcinoma+of+Stomach&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T10:07:14.320Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03576131", "title": "GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Renal Cell Carcinoma", "Gastric Cancer", "Pancreatic Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "GEN1029 (HexaBody®-DR5/DR5)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-04-30", "completion_date": "2021-10-12", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03576131" }, { "nct_id": "NCT06943521", "title": "A Study of MT-4561 in Patients With Various Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Cancer", "Gastric Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "Prostate Cancer", "Urothelial Carcinoma", "Neuroendocrine Tumor (NET)", "Neuroendocrine Carcinoma (NEC)", "Soft Tissue Sarcoma", "Nuclear Protein in Testis (NUT) Carcinoma" ], "interventions": [ { "name": "MT-4561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanabe Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-04-18", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943521" }, { "nct_id": "NCT03861793", "title": "A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ALKS 4230", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mural Oncology, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2019-02-26", "completion_date": "2023-03-01", "has_results": false, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 17, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03861793" }, { "nct_id": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Urothelial Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Gastric Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Microsatellite Instability", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "N-803 + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Nivolumab", "type": "DRUG" }, { "name": "N-803 + Atezolizumab", "type": "DRUG" }, { "name": "N-803 + Avelumab", "type": "DRUG" }, { "name": "N-803 + Durvalumab", "type": "DRUG" }, { "name": "N-803 + Pembrolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Nivolumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Atezolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Avelumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Durvalumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-12-11", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 35, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228667" }, { "nct_id": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head & Neck Squamous Cell Carcinoma", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Colorectal Cancer", "Endometrial Cancer", "Urothelial Carcinoma (UC)", "Breast Cancer" ], "interventions": [ { "name": "STRO-006", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2026-09-14", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 7, "location_summary": "La Jolla, California • Orlando, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807345" }, { "nct_id": "NCT05229900", "title": "A Study of SGN-ALPV in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Endometrial Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Stomach Neoplasms", "Gastroesophageal Junction Carcinoma", "Uterine Cervical Neoplasms", "Testicular Neoplasms" ], "interventions": [ { "name": "SGN-ALPV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2022-04-21", "completion_date": "2023-12-13", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 7, "location_summary": "Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Wellington", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05229900" }, { "nct_id": "NCT04727151", "title": "TAC T-cells for the Treatment of HER2-positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2 Positive Gastric Cancer", "Metastatic HER2 Positive Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "TAC01-HER2", "type": "BIOLOGICAL" }, { "name": "TAC01-HER2 plus pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Triumvira Immunologics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2021-04-19", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 9, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Newark, New Jersey + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04727151" }, { "nct_id": "NCT03071757", "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2017-03-21", "completion_date": "2022-04-13", "has_results": false, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 10, "location_summary": "La Jolla, California • Sacramento, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071757" }, { "nct_id": "NCT05334069", "title": "Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Ann Arbor Stage I Lymphoma", "Ann Arbor Stage II Lymphoma", "Ann Arbor Stage III Lymphoma", "Ann Arbor Stage IV Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myeloid Leukemia", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Invasive Breast Carcinoma", "Kidney Carcinoma", "Malignant Hepatobiliary Neoplasm", "Malignant Solid Neoplasm", "Melanoma", "Muscle-Invasive Bladder Carcinoma", "RISS Stage I Plasma Cell Myeloma", "RISS Stage II Plasma Cell Myeloma", "RISS Stage III Plasma Cell Myeloma", "Sarcoma", "Stage I Bladder Cancer AJCC v6 and v7", "Stage I Breast Cancer AJCC v7", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Esophageal Cancer AJCC V7", "Stage I Gastric Cancer AJCC V7", "Stage I Lung Cancer AJCC v7", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage I Pancreatic Cancer AJCC v6 and v7", "Stage I Prostate Cancer AJCC v7", "Stage I Uterine Corpus Cancer AJCC v7", "Stage II Bladder Cancer AJCC v6 and v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage II Colorectal Cancer AJCC v7", "Stage II Esophageal Cancer AJCC v7", "Stage II Gastric Cancer AJCC v7", "Stage II Lung Cancer AJCC v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage II Pancreatic Cancer AJCC v6 and v7", "Stage II Prostate Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage III Bladder Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Esophageal Cancer AJCC v7", "Stage III Gastric Cancer AJCC v7", "Stage III Lung Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Prostate Cancer AJCC v7", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IV Bladder Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Stage IV Lung Cancer AJCC v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 2000, "start_date": "2022-08-18", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 747, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 502 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05334069" }, { "nct_id": "NCT02500199", "title": "Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Gastric Cancer", "Solid Tumors", "NSCLC" ], "interventions": [ { "name": "Pyrotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hengrui Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-06", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-10-15T10:07:14.320Z", "location_count": 10, "location_summary": "Orange, California • Sacramento, California • Sarasota, Florida + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500199" } ] }